OR WAIT 15 SECS
How has India's biosimilars landscape evolved over the past 25 years, and what have been the most significant ...
Maharashtra Governor C.P. Radhakrishnan inaugurated the newly revamped Aditya Jyot Eye Hospital in Wadala, Mum...
In 2024, the bioeconomy of India reached a value of $165.7 billion, reflecting strong growth across biopharma,...
India has emerged as a key player in the global biopharmaceutical industry, and with the rapid expansion of bi...
25 Transformative Years of BIOSIMILARS
2025 marks 25 years since India first ventured into the biosimilar space. Over the past quarter century, the country has consistently solidified its position as a global leader in biosimilar approvals, with 135 approvals till January 2025. Initially focused on simpler biologics, the field now includes developing and approving complex monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), a diversified therapeutic focus, and a growing number of innovative players entering the field. As the industry celebrates this silver jubilee, we reflect on the journey that has not only transformed India's biotechnology sector but has also played a pivotal role in making life saving treatments more accessible and affordable worldwide.
For Feedback, please email us at: communications@mmactiv.com
Sign up here to access BioSpectrum India Flip Book.
Sign up here to access BioSpectrum India Flip Book
